Steroids and sepsis: Time for another reevaluation

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Treatment of sepsis has changed little in the past few decades and the lack of improvement is reflected in the relatively steady mortality rate. Much of the initial disappointment surrounding many of the past multicentered clinical trials in sepsis centers on the use of short-term, high-dose steroids. While recent advances focusing on the interplay between inflammation and coagulation are expected to result in important new treatments in sepsis, rekindled enthusiasm for the role of supraphysiologic-dose steroids is adding to the excitement. Specifically, emerging evidence suggests that moderate-dose glucocorticoids may improve outcomes in septic shock patients, in part, by treating occult adrenal insufficiency. One preliminary study that has sparked considerable interest reported a 30% relative reduction in mortality in sepsis patients treated with modest doses of hydrocortisone for 1 week. It appears clear the role of adrenal insufficiency and steroids in septic shock is deserving of a reevaluation.

Original languageEnglish (US)
Pages (from-to)68-74
Number of pages7
JournalJournal of Intensive Care Medicine
Volume17
Issue number2
DOIs
StatePublished - 2002

Fingerprint

Sepsis
Steroids
Adrenal Insufficiency
Septic Shock
Mortality
Glucocorticoids
Hydrocortisone
Clinical Trials
Inflammation
Therapeutics

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine

Cite this

Steroids and sepsis : Time for another reevaluation. / Kenyon, Nicholas; Albertson, Timothy E.

In: Journal of Intensive Care Medicine, Vol. 17, No. 2, 2002, p. 68-74.

Research output: Contribution to journalArticle

@article{90667e09ccca4a46b9e996694820d9a0,
title = "Steroids and sepsis: Time for another reevaluation",
abstract = "Treatment of sepsis has changed little in the past few decades and the lack of improvement is reflected in the relatively steady mortality rate. Much of the initial disappointment surrounding many of the past multicentered clinical trials in sepsis centers on the use of short-term, high-dose steroids. While recent advances focusing on the interplay between inflammation and coagulation are expected to result in important new treatments in sepsis, rekindled enthusiasm for the role of supraphysiologic-dose steroids is adding to the excitement. Specifically, emerging evidence suggests that moderate-dose glucocorticoids may improve outcomes in septic shock patients, in part, by treating occult adrenal insufficiency. One preliminary study that has sparked considerable interest reported a 30{\%} relative reduction in mortality in sepsis patients treated with modest doses of hydrocortisone for 1 week. It appears clear the role of adrenal insufficiency and steroids in septic shock is deserving of a reevaluation.",
author = "Nicholas Kenyon and Albertson, {Timothy E}",
year = "2002",
doi = "10.1046/j.1525-1489.2002.17202.x",
language = "English (US)",
volume = "17",
pages = "68--74",
journal = "Journal of Intensive Care Medicine",
issn = "0885-0666",
publisher = "SAGE Publications Inc.",
number = "2",

}

TY - JOUR

T1 - Steroids and sepsis

T2 - Time for another reevaluation

AU - Kenyon, Nicholas

AU - Albertson, Timothy E

PY - 2002

Y1 - 2002

N2 - Treatment of sepsis has changed little in the past few decades and the lack of improvement is reflected in the relatively steady mortality rate. Much of the initial disappointment surrounding many of the past multicentered clinical trials in sepsis centers on the use of short-term, high-dose steroids. While recent advances focusing on the interplay between inflammation and coagulation are expected to result in important new treatments in sepsis, rekindled enthusiasm for the role of supraphysiologic-dose steroids is adding to the excitement. Specifically, emerging evidence suggests that moderate-dose glucocorticoids may improve outcomes in septic shock patients, in part, by treating occult adrenal insufficiency. One preliminary study that has sparked considerable interest reported a 30% relative reduction in mortality in sepsis patients treated with modest doses of hydrocortisone for 1 week. It appears clear the role of adrenal insufficiency and steroids in septic shock is deserving of a reevaluation.

AB - Treatment of sepsis has changed little in the past few decades and the lack of improvement is reflected in the relatively steady mortality rate. Much of the initial disappointment surrounding many of the past multicentered clinical trials in sepsis centers on the use of short-term, high-dose steroids. While recent advances focusing on the interplay between inflammation and coagulation are expected to result in important new treatments in sepsis, rekindled enthusiasm for the role of supraphysiologic-dose steroids is adding to the excitement. Specifically, emerging evidence suggests that moderate-dose glucocorticoids may improve outcomes in septic shock patients, in part, by treating occult adrenal insufficiency. One preliminary study that has sparked considerable interest reported a 30% relative reduction in mortality in sepsis patients treated with modest doses of hydrocortisone for 1 week. It appears clear the role of adrenal insufficiency and steroids in septic shock is deserving of a reevaluation.

UR - http://www.scopus.com/inward/record.url?scp=0036175198&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036175198&partnerID=8YFLogxK

U2 - 10.1046/j.1525-1489.2002.17202.x

DO - 10.1046/j.1525-1489.2002.17202.x

M3 - Article

AN - SCOPUS:0036175198

VL - 17

SP - 68

EP - 74

JO - Journal of Intensive Care Medicine

JF - Journal of Intensive Care Medicine

SN - 0885-0666

IS - 2

ER -